| Training group | Testing group | ||
---|---|---|---|---|
Benign lesions# | 1.3(0.5-3.0)cm | 1.8(0.5-9.0) | ||
Malignant lesions# | 2.8(1.5-5.0)cm | 2.6(0.5-5.5)cm | ||
 | Number | Percentage | Number | Percentage |
BI-RADS assessments | Â | Â | Â | Â |
category 2 | 30 | 12.8 | 17 | 18.3 |
category 3 | 41 | 17.6 | 41 | 44.1 |
category 4 | 98 | 41.8 | 27 | 29.0 |
category 5 | 65 | 27.8 | 8 | 8.6 |
Malignant lesions | 149 | 63.68 | 75 | 80.6 |
  Invasive ductal carcinoma | 120 | 51.3 | 62 | 66.7 |
  Intraductal carcinoma | 17 | 7.26 | 9 | 9.7 |
  Ductal carcinoma in situ | 4 | 1.7 | 1 | 1.1 |
  Mucinous carcinoma | 3 | 1.28 | 2 | 2.1 |
  Medullary carcinoma | 1 | 0.43 | 0 | 0 |
  Others | 4 | 1.71 | 1 | 1.1 |
Benign lesions | 85 | 36.32 | 18 | 19.4 |
  Fibroadenoma | 26 | 11.11 | 6 | 6.4 |
  Fibrocystic changes | 24 | 10.26 | 3 | 3.2 |
  Fibroadenosis | 3 | 1.28 | 3 | 3.2 |
  Intraductal papilloma | 4 | 1.71 | 3 | 3.2 |
  Hyperplasia | 3 | 1.28 | 1 | 1.1 |
Phyllodestumor | 2 | 0.85’ | 1 | 1.1 |
Adenomyosisepithelioma | 1 | 0.43 | 0 | 0 |
  Inflammation | 1 | 0.43 | 1 | 1.1 |
  Follow-up | 21 | 8.97 | 0 | 0 |